1. The CD16 and CD32b Fc-gamma receptors regulate antibody-mediated responses in mouse natural killer cells.
- Author
-
Aguilar, Oscar A, Gonzalez-Hinojosa, Maria DR, Arakawa-Hoyt, Janice S, Millan, Alberto J, Gotthardt, Dagmar, Nabekura, Tsukasa, and Lanier, Lewis L
- Subjects
Biomedical and Clinical Sciences ,Immunology ,Immunization ,Vaccine Related ,Prevention ,Cancer ,1.1 Normal biological development and functioning ,2.1 Biological and endogenous factors ,Underpinning research ,Aetiology ,Inflammatory and immune system ,Mice ,Animals ,Immunity ,Innate ,Receptors ,IgG ,Cytotoxicity ,Immunologic ,Killer Cells ,Natural ,Antibodies ,Lymphoma ,B-Cell ,natural killer cells ,NK ,Fc receptor ,Fc gamma RIII ,CD16 ,Fc gamma RIIb ,CD32b ,antibodies ,FcγRIII ,FcγRIIb ,Biochemistry and Cell Biology - Abstract
Natural killer (NK) cells are innate lymphocytes capable of mediating immune responses without prior sensitization. NK cells express Fc-gamma receptors (FcγRs) that engage the Fc region of IgG. Studies investigating the role of FcγRs on mouse NK cells have been limited due to lack specific reagents. In this study, we characterize the expression and biological consequences of activating mouse NK cells through their FcγRs. We demonstrate that most NK cells express the activating CD16 receptor, and a subset of NK cells also expresses the inhibitory CD32b receptor. Critically, these FcγRs are functional on mouse NK cells and can modulate antibody-mediated responses. We also characterized mice with conditional knockout alleles of Fcgr3 (CD16) or Fcgr2b (CD32b) in the NK and innate lymphoid cell (ILC) lineage. NK cells in these mice did not reveal any developmental defects and were responsive to cross-linking activating NK receptors, cytokine stimulation, and killing of YAC-1 targets. Importantly, CD16-deficient NK cells failed to induce antibody-directed cellular cytotoxicity of antibody-coated B-cell lymphomas in in vitro assays. In addition, we demonstrate the important role of CD16 on NK cells using an in vivo model of cancer immunotherapy using anti-CD20 antibody treatment of B-cell lymphomas.
- Published
- 2023